Sean Mulryan invests in Zoosh Group
25th April 2022: Ballymore Group founder and Group CEO Sean Mulryan has acquired a significant…
News
Progenity Appoints Paul Shabram to Lead Technical Operations of the Company’s Ingestible Drug/Device Platforms
Expanding Leadership Team to Accelerate Development of Innovative Therapeutic Delivery Platforms SAN DIEGO, April 25,…
Castellum, Inc. Hires David T. Bell as Chief Financial Officer
Castellum, Inc. Hires David T. Bell as Chief Financial Officer Castellum, Inc. (OTC: ONOV) announces…
Black Diamond Therapeutics Announces Pipeline Prioritization and Workforce Realignment
– Strategic areas of focus on development of BDTX-1535 and BDTX-4933 as well as MAP…
Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference
– Q&A Session at Conference on Wednesday, April 27th at 1:30PM Eastern – AUSTIN, Texas,…
Dr. Henry Ji, Sorrento Therapeutics’ Chairman and CEO and Scilex Holding Company’s Executive Chairman, to Present at the B. Riley Securities’ 2022 Virtual Neuro & Opthalmology Healthcare Conference (April 27-28, 2022)
SAN DIEGO and PALO ALTO, Calif., April 25, 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc….
Acasti Pharma to Present at the B. Riley Securities’ 2022 Virtual Neuro & Ophthalmology Conference on April 28th
LAVAL, Québec, April 25, 2022 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”)…
Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & Infectious Diseases
MIAMI, April 25, 2022 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, today…
Radius Health to Release First Quarter 2022 Financial Results, Host Conference Call and Live Webcast on Thursday, May 5, 2022
BOSTON, April 25, 2022 (GLOBE NEWSWIRE) — Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:…
Quoin Pharmaceuticals Announces FDA Clearance of IND for its Lead Asset, QRX003, for Netherton Syndrome
Quoin Will Initiate Clinical Testing in 1H 2022 ASHBURN, Va., April 25, 2022 (GLOBE NEWSWIRE)…
Wave Life Sciences Announces Publication of Foundational Preclinical Data Supporting Development of WVE-004 for C9orf72-associated ALS and FTD
Preclinical data published in Molecular Therapy Nucleic Acids demonstrate that WVE-004 potently reduces C9orf72 transcriptional…
CB Therapeutics rapidly expands cellular agriculture capabilities at new facility
Chief Science Officer and CB Therapeutics co-founder, Dr. Jacob Vogan, working alongside Laboratory Manager, Diana…
Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022
The Company to Host a Conference Call and Webcast on May 11, 2022, at 8:30…
Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022™, the Annual Event of the American Association of Immunologists
– Company advancing development of its Autoimmunity Modifying AIM Biologicals as a potential therapeutic treatment…
Applied Molecular Transport Announces Positive Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis
– Met pre-specified efficacy endpoints in chronic pouchitis, a difficult-to-treat inflammatory bowel disease (IBD)– AMT-101…
Cognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
PURCHASE, N.Y., April 25, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical…
Avadel Pharmaceuticals Announces Interim Data from the Open-Label RESTORE Study at the 2022 American Academy of Neurology Annual Meeting
Results from patient preference questionnaire indicate that people with narcolepsy preferred the once-nightly over the…
Sunshine Biopharma Files Patent Application Covering Recently Announced mRNA Molecules Found To Be Effective At Destroying Multidrug Resistant Cancer Cells
MONTREAL, April 25, 2022 (GLOBE NEWSWIRE) — Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a…
Portage Biotech Enters Cooperative Research and Development Agreement with U.S. National Cancer Institute and Stimunity
Collaboration will advance preclinical and potential clinical development of STING agonists and anti-RAGE agents for…
Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular (“Tandem”) Meetings of ASTCT and CIBMTR
Interim analysis provides response data from 7 evaluable patients including two additional patients, one with…